Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00363545
Status:
COMPLETED
Last Update Posted:
2018-06-08
First Post:
2006-08-11
Brief Title:
To Assess Immunogenicity Reactogenicity Safety of 2 Formulations of GSKs HRV Vaccine as 2-dose Vaccination Infants
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Study to Assess the Immunogenicity Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals Live Attenuated HRV Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will be conducted to evaluate the immunogenicity reactogenicity and safety of the liquid formulation of GSK Biologicals HRV vaccine compared to the lyophilized formulation of GSK Biologicals HRV vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None